What was the primary driver of the significant increase in net sales?

The primary driver of the significant increase in net sales was the acquisition of the pharmaceutical business of BASF, known as Knoll Pharmaceuticals, which closed on March 2, 2001. This acquisition substantially expanded Abbott's Pharmaceutical and International segments.

Why did earnings per share decrease despite revenue growth?

Diluted earnings per share decreased to $0.34 from $0.44 year-over-year primarily due to significant one-time charges. These included a $172 million charge for acquired in-process research and development and restructuring charges related to the integration of the BASF acquisition. Additionally, increased amortization of goodwill and intangible assets from the acquisition also impacted earnings.

How has the acquisition of Knoll impacted Abbott's balance sheet and cash flow?

The acquisition of Knoll significantly increased Abbott's assets, particularly intangible assets and goodwill, and also led to a substantial increase in long-term debt and short-term borrowings to finance the $7.0 billion purchase price. This is reflected in the balance sheet with higher levels of debt and a decrease in cash and cash equivalents due to the large cash outflow for the acquisition, which resulted in a significant net cash outflow from investing activities.

What are the key risks or uncertainties highlighted in the report?

Key risks and uncertainties include ongoing litigation, particularly the U.S. Department of Justice investigation into TAP Pharmaceutical Products Inc. and related lawsuits, as well as antitrust litigation concerning HYTRIN. The company is also subject to regulatory compliance, specifically the FDA's consent decree for its diagnostics manufacturing operations and the review process for its SYNTHROID product. Potential legislative changes in healthcare are also noted as a factor that could impact pricing and services.

ABT 10-Q Quarterly Report Q2 FY2001 — Revenue, Net Income, EPS

Summary

Abbott Laboratories reported solid revenue growth driven by a significant expansion in its Pharmaceutical and International segments, largely attributable to the acquisition of BASF's pharmaceutical business in March 2001. While consolidated net sales increased notably, the company experienced a decline in diluted earnings per share for the quarter compared to the prior year, primarily due to substantial one-time charges. These include a significant investment in acquired in-process research and development and restructuring costs associated with the BASF acquisition. The company's financial position was impacted by increased short-term borrowings to fund the acquisition, though this was subsequently refinanced with long-term debt. Investors should note the strategic shift towards a larger pharmaceutical footprint following the Knoll acquisition, which has increased the company's asset base and debt levels but also offers significant growth potential. Management is focused on integrating the acquired business and navigating ongoing litigation, particularly concerning the TAP joint venture, though they express confidence that these matters will not materially impact the company's financial standing. The company also faces regulatory considerations, such as the FDA's requirements for its diagnostics manufacturing and the review of its SYNTHROID product.

Key Highlights

1Net sales for the second quarter of 2001 increased by 21.6% to $4.099 billion, driven by strong performance in the Pharmaceutical and International segments.
2The acquisition of BASF's pharmaceutical business (Knoll) for approximately $7.0 billion significantly impacted the financial statements, leading to substantial increases in acquired in-process R&D, intangible assets, and goodwill.
3Diluted earnings per share decreased to $0.34 for the quarter ended June 30, 2001, down from $0.44 in the prior year's comparable quarter, mainly due to significant one-time charges.
4Total operating costs and expenses rose sharply, driven by the inclusion of acquired in-process R&D ($172 million for the quarter) and increased selling, general, and administrative expenses.
5Net cash used in investing activities surged to $7.2 billion, predominantly due to the $6.8 billion acquisition of the BASF pharmaceutical business.
6The company reported $56.7 million in accrued restructuring charges as of June 30, 2001, related to the integration of the acquired BASF operations.
7Abbott took a $344 million increase in its litigation reserve in the first quarter of 2001 related to the U.S. Department of Justice investigation into TAP Pharmaceutical Products Inc.

ABBOTT LABORATORIES Quarterly Report for Q2 Ended Jun 30, 2001

Summary

Key Highlights

Frequently Asked Questions